---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-299165"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-07-09T12:00:16+00:00"
generated_at: "2026-07-09T12:05:10.609456+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics announces CRO transition: Turner to Special Advisor, Bowman appointed Chief Regulatory Officer

## Summary
- William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.
- Nancy Bowman, M.D., Ph.D., appointed as new Chief Regulatory Officer, effective August 3, 2026.
- Transition appears planned; no reason for departure given.

## SEC filing metadata
- accession: 0001193125-26-299165
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-07-09T12:00:16+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/0001193125-26-299165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526299165/vera-20260709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-299165
- JSON: https://secwatch.observer/filing/0001193125-26-299165.json
- Plain text: https://secwatch.observer/filing/0001193125-26-299165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.